Free Trial

iRadimed (IRMD) Stock Price, News & Analysis

iRadimed logo
$85.35 +0.12 (+0.14%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$85.11 -0.24 (-0.28%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About iRadimed Stock (NASDAQ:IRMD)

Advanced

Key Stats

Today's Range
$84.29
▼
$86.17
50-Day Range
$76.68
▼
$89.83
52-Week Range
$76.35
▼
$107.90
Volume
115,215 shs
Average Volume
129,085 shs
Market Capitalization
$1.09 billion
P/E Ratio
45.64
Dividend Yield
0.94%
Price Target
$120.00
Consensus Rating
Buy

Company Overview

iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. Its products include MRI-compatible patient monitoring systems and intravenous infusion pumps, along with related accessories.

The company’s monitoring systems help clinicians track patients during MRI procedures, while its infusion pumps deliver fluids and medications in the MRI suite. iRadimed’s equipment is designed to operate in the presence of MRI magnets, where conventional medical devices may not be suitable.

Based in Winter Springs, Florida, iRadimed serves hospitals and other medical facilities in the United States and internationally. The company was founded in 2004 by Roger Susi, who has led its development of MRI-compatible medical equipment.

AI Generated. May Contain Errors.

iRadimed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

IRMD MarketRank™: 
3.39895013123 of 5 stars

iRadimed scored higher than 68% of companies evaluated by MarketBeat, and ranked 253rd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    iRadimed has a consensus price target of $120.00, representing about 40.6% upside from its current price of $85.35.

  • Amount of Analyst Coverage

    iRadimed has only been the subject of 2 research reports in the past 90 days.

  • Read more about iRadimed's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iRadimed is 45.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.40.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iRadimed is 45.64, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.

  • Price to Book Value per Share Ratio

    iRadimed has a P/B Ratio of 10.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.06% of the float of iRadimed has been sold short.
  • Short Interest Ratio / Days to Cover

    iRadimed has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in iRadimed has recently decreased by 11.96%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    iRadimed has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    iRadimed has only been increasing its dividend for 1 years.

  • Dividend Coverage

    The dividend payout ratio of iRadimed is 42.78%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about iRadimed's dividend.
  • News Sentiment

    iRadimed has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for iRadimed this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,616.00 in company stock.

  • Percentage Held by Insiders

    34.60% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about iRadimed's insider trading history.
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iRadimed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRMD Stock News Headlines

Is IRADIMED (IRMD) Fully Priced Based On Future Cash Flow?
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Iradimed (IRMD) Q3 2026 Earnings Call Transcript
Iradimed Posts Record Q3 Revenue, Eyes $100M Run Rate
See More Headlines

IRMD Stock Analysis - Frequently Asked Questions

iRadimed's stock was trading at $97.28 at the beginning of the year. Since then, IRMD stock has decreased by 12.3% and is now trading at $85.35.

iRadimed Corporation (NASDAQ:IRMD) posted its earnings results on Friday, October, 30th. The medical equipment provider reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. The medical equipment provider earned $24.20 million during the quarter, compared to analyst estimates of $23.47 million. iRadimed had a trailing twelve-month return on equity of 23.90% and a net margin of 26.85%.
Read the conference call transcript
.

iRadimed (IRMD) raised $13 million in an IPO on Wednesday, July 16th 2014. The company issued 2,016,000 shares at $6.25 per share.

iRadimed's top institutional investors include Copeland Capital Management LLC (2.99%), State Street Corp (1.86%), Bridge City Capital LLC (0.76%) and Russell Investments Group Ltd. (0.51%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen and John Glenn.
View institutional ownership trends
.

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Alphabet (GOOG), Tesla (TSLA) and Pfizer (PFE).

Company Calendar

Record date for 8/28 Dividend
8/14/2026
Ex-Dividend for 8/28 Dividend
8/14/2026
Dividend Payable
8/28/2026
Last Earnings
10/30/2026
Record date for 11/27 Dividend
11/13/2026
Ex-Dividend for 11/27 Dividend
11/13/2026
Today
11/15/2026
Dividend Payable
11/27/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:IRMD
CIK
1325618
Employees
166
Year Founded
2004

Price Target and Rating

High Price Target
$120.00
Low Price Target
$120.00
Potential Upside/Downside
+40.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.87
Trailing P/E Ratio
45.64
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$22.48 million
Net Margins
26.85%
Pretax Margin
34.83%
Return on Equity
23.90%
Return on Assets
20.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.99
Quick Ratio
7.68

Sales & Book Value

Annual Sales
$89.34 million
Price / Sales
12.22
Cash Flow
$1.86 per share
Price / Cash Flow
45.85
Book Value
$8.32 per share
Price / Book
10.26

Miscellaneous

Outstanding Shares
12,788,000
Free Float
8,363,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
0.91

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:IRMD) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners